NO974076L - Reduksjon av infarktvolum ved å anvende citicolin - Google Patents

Reduksjon av infarktvolum ved å anvende citicolin

Info

Publication number
NO974076L
NO974076L NO974076A NO974076A NO974076L NO 974076 L NO974076 L NO 974076L NO 974076 A NO974076 A NO 974076A NO 974076 A NO974076 A NO 974076A NO 974076 L NO974076 L NO 974076L
Authority
NO
Norway
Prior art keywords
citicoline
reduction
treatment
infarct volume
infarction
Prior art date
Application number
NO974076A
Other languages
English (en)
Other versions
NO974076D0 (no
NO313538B1 (no
Inventor
Bobby Winston Sandage
Marc Fisher
Kenneth W Locke
Original Assignee
Interneuron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO974076(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/603,102 external-priority patent/US5872108A/en
Priority claimed from US08/609,448 external-priority patent/US5827832A/en
Application filed by Interneuron Pharma filed Critical Interneuron Pharma
Publication of NO974076D0 publication Critical patent/NO974076D0/no
Publication of NO974076L publication Critical patent/NO974076L/no
Publication of NO313538B1 publication Critical patent/NO313538B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicinal Preparation (AREA)
NO19974076A 1995-03-06 1997-09-04 Anvendelse av citicolin samt farmasöytisk preparat NO313538B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39926295A 1995-03-06 1995-03-06
US08/603,102 US5872108A (en) 1995-03-06 1996-02-20 Reduction of infarct volume using citicoline
US08/609,448 US5827832A (en) 1995-03-06 1996-03-01 Method of protecting brain tissue from cerebral infarction subsequent to ischemia
PCT/US1996/003159 WO1996027380A1 (en) 1995-03-06 1996-03-06 Reduction of infarct volume using citicoline

Publications (3)

Publication Number Publication Date
NO974076D0 NO974076D0 (no) 1997-09-04
NO974076L true NO974076L (no) 1997-10-28
NO313538B1 NO313538B1 (no) 2002-10-21

Family

ID=27410335

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974076A NO313538B1 (no) 1995-03-06 1997-09-04 Anvendelse av citicolin samt farmasöytisk preparat

Country Status (14)

Country Link
EP (1) EP0813416B1 (no)
JP (1) JPH11511732A (no)
CN (2) CN1126546C (no)
AT (1) ATE296103T1 (no)
AU (1) AU5304796A (no)
BR (1) BR9607206A (no)
CA (1) CA2213000A1 (no)
DE (1) DE69634773T2 (no)
ES (1) ES2244968T3 (no)
MX (1) MX9706808A (no)
NO (1) NO313538B1 (no)
PL (1) PL185124B1 (no)
PT (1) PT813416E (no)
WO (1) WO1996027380A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
EP1041992A4 (en) * 1997-12-24 2007-05-09 Ferrer Int HYPERHYDRATED CITICOLIN, THE PRODUCTION THEREOF AND ITS USE
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
ES2169986B1 (es) * 2000-03-14 2003-06-16 Ferrer Int Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral.
BR0213325A (pt) 2001-10-15 2004-10-13 Janssen Pharmaceutica Nv Derivados de 4-fenil-4-[1h-imidazol-2-il]-piperidina substituìda para a redução de dano isquêmico
ES2345802B1 (es) * 2009-03-30 2011-09-08 Hospital Clinic I Provincial De Barcelona Composicion farmaceutica para el tratamiento neuroprotector en pacientes con ictus.
WO2013179910A1 (ja) 2012-05-31 2013-12-05 学校法人近畿大学 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
JP6166786B2 (ja) * 2012-10-30 2017-07-19 協和発酵バイオ株式会社 脳機能低下の予防または改善剤
CN105769882B (zh) * 2016-03-14 2019-02-22 北京赛德维康医药研究院 一种抑制血栓形成的药物组合物及其用途
KR102442669B1 (ko) 2017-05-09 2022-09-13 호스피탈 크리닉 드 바르셀로나 기계적 혈전제거술로써 치료된 뇌졸중 환자의 치료를 위한 요산을 포함하는 조성물
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
IT1207106B (it) * 1980-04-18 1989-05-17 Made Italiana Srl Ora Searle I Preparazione farmaceutica contenente citidin disfofocolina assorbibile per via orale

Also Published As

Publication number Publication date
EP0813416A1 (en) 1997-12-29
ATE296103T1 (de) 2005-06-15
JPH11511732A (ja) 1999-10-12
AU5304796A (en) 1996-09-23
NO974076D0 (no) 1997-09-04
CN1181015A (zh) 1998-05-06
EP0813416A4 (en) 2000-11-15
MX9706808A (es) 1998-08-30
CA2213000A1 (en) 1996-09-12
CN1126546C (zh) 2003-11-05
NO313538B1 (no) 2002-10-21
BR9607206A (pt) 1997-11-11
CN1488353A (zh) 2004-04-14
DE69634773D1 (de) 2005-06-30
DE69634773T2 (de) 2006-05-04
ES2244968T3 (es) 2005-12-16
PT813416E (pt) 2005-10-31
PL322061A1 (en) 1998-01-05
PL185124B1 (pl) 2003-02-28
EP0813416B1 (en) 2005-05-25
WO1996027380A1 (en) 1996-09-12

Similar Documents

Publication Publication Date Title
NO974076D0 (no) Reduksjon av infarktvolum ved å anvende citicolin
EP1014996A4 (en) SACCHARIDE COMPOSITIONS AND METHODS FOR SPECIFIC TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSIS
GR3007251T3 (no)
EP0703785B8 (en) Methods for treating muscle diseases and disorders
BG102600A (en) Carbamoyloxy derivatives of mutilin and their use as bactericides
HK1007102A1 (en) Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma
DK0665749T3 (da) Sammensætning til behandling af Parkinsons sygdom
EP0906307A4 (en) SUBSTITUTED IMIDAZOLES WITH CYTOKININ INHIBIRING EFFECT
EP0945135A3 (en) Treatment of alzheimer's disease and modulation of immune system with Delta5-Androstenes
BG97068A (bg) Фармацевтичен състав и метод за постигане на терапевтичен ефект
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
RU94044490A (ru) Применение 2-фенил-3-ароилбензотиофенов для подавления дефектного восстановления ткани
AU4385399A (en) Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer
EP1294375A4 (en) METHOD FOR THE TREATMENT OF SEBORRHOIC DERMATITIS
CA2140361A1 (en) Composition and methods for decreasing muscle breakdown
MXPA04004826A (es) Antagonista del receptor de quimioquinas y metodos para su uso.
NZ299006A (en) Use of 4-dichlorophenyl tetrahydro N-methyl-1-naphthalenamine (sertraline) for heart attack treatment
SE9302333D0 (sv) New compounds
Almeida et al. Effects of a purified scorpion toxin (tityustoxin) on the isolated guinea pig heart
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
ES2194907T3 (es) Utilizacion de la espiramicina en desordenes gastro-intestinales debido al h.pylori.
MX9602793A (es) Uso de sertralina para tratar pacientes despues de un infarto de miocardio.
EP0621789A4 (en) Pharmaceutical pentapeptide compositions and methods of use thereof.

Legal Events

Date Code Title Description
MK1K Patent expired